Show Search Form

Search Results

human indexable	true false
published	true false
registered interest	true false
answer date	exactly: or between: and
date	exactly: or between: and
date tabled	exactly: or between: and
ddp created	exactly: or between: and
ddp modified	exactly: or between: and
answering body
question status
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
identifier
legislature
parliament number
question first answered
question text
session
session number
tabling member constituency
tabling member printed
title
type
uin
version
written parliamentary question type
answer	answer text
creator	label
publisher
tabling member	label

Search

156676

	human indexable
	published
	registered interest
	answer date	21/11/2014
	date	19/11/2014
	date tabled	19/11/2014
	ddp created	19/11/2014 23:42:11
	ddp modified	08/02/2015 10:16:50
	answering body	Department of Health
	question status	Tabled
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus: Vaccination
	house id	1
	identifier	215364
	legislature	25259
	parliament number	55
	question first answered	26/11/2014 17:37:21
	question text	To ask the Secretary of State for Health, what estimate his Department has made of the take up of the HPV vaccine in (a) Lambeth, (b) Greater London and (c) the UK for each ethnic group.
	session	2014/15
	session number	4
	tabling member constituency	Streatham
	tabling member printed	Mr Chuka Umunna
	title	House of Commons Tabled Parliamentary Question 2014/15 215364
	type	WrittenParliamentaryQuestion
	uin	215364
	version	1
	written parliamentary question type	Ordinary
	answer	answer answer text <p>HPV vaccination uptake data by ethnicity is not routinely collected and collated nationally. Accordingly it is not possible to provide information relating to the take up of the HPV vaccine in Lambeth, Greater London and the United Kingdom for each ethnic group.</p><p> </p><p> </p><p> </p><p>Some studies conducted in England have demonstrated lower vaccination uptake in non-white ethnic groups. Sacks et al<sup>1</sup> reported 3-dose HPV vaccination coverage among young women attending sexual health services across England of 72% among the White ethnic group, 56% in the Asian ethnic group and 55% in the Black ethnic group. Bowyer et al<sup>2 </sup> showed that among young girls attending school in London, those from non-white ethnic backgrounds were significantly less likely to report having received all three doses of the HPV vaccine than those from the white ethnic group.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><sup>1</sup>Sacks RJ, Copas AJ, Wilkinson DM, Robinson AJ. Uptake of the HPV vaccination programme in England: a cross-sectional survey of young women attending sexual health services. Sex Transm Infect 2014 Jun;90(4):315-21.</p><p> </p><p><sup>2</sup>Bowyer HL, Dodd RH, Marlow LA, Waller J. Association between human papillomavirus vaccine status and other cervical cancer risk factors. Vaccine 2014 Jul 23;32(34):4310-6.</p><p> </p><p><strong> </strong></p><p> </p>
	creator	4128 label Biography information for Chuka Umunna
	publisher	25259
	tabling member	4128 label Biography information for Chuka Umunna

167280

	human indexable
	published
	registered interest
	answer date	16/12/2014
	date	02/12/2014
	date tabled	02/12/2014
	ddp created	02/12/2014 22:28:53
	ddp modified	06/02/2015 19:45:21
	answering body	Department of Health
	question status	Tabled
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus: Vaccination
	house id	2
	identifier	HL3381
	legislature	25277
	parliament number	55
	question first answered	16/12/2014 15:34:13
	question text	To ask Her Majesty’s Government how many adverse reactions to Cervarix, Gardasil and unbranded human papilloma virus vaccines have been reported to the Medicines and Healthcare Products Regulatory Agency up to the most recent date; how many of those reports are of serious adverse reactions for each category; and what is the age specific rate that these figures represent.
	session	2014/15
	session number	4
	tabling member printed	The Countess of Mar
	title	House of Lords Tabled Parliamentary Question 2014/15 HL3381
	type	WrittenParliamentaryQuestion
	uin	HL3381
	version	1
	written parliamentary question type	Ordinary
	answer	answer answer text <p>A total of 7947 suspected adverse reaction reports with human papilloma virus (HPV) vaccines have been reported to the Medicines and Healthcare Products Regulatory Agency (MHRA) via the Yellow Card Scheme up to 3 December 2014. It is important to note that a Yellow Card report is not proof of a side effect occurring, but a suspicion by the reporter that the vaccine may have been the cause. The frequency of known side effects is listed in the product information (the Summary of Product Characteristics for health professionals and the Patient Information Leaflet) which are provided with the vaccines.</p><p> </p><p> </p><p> </p><p>The following table provides a breakdown of these reports by brand and seriousness.</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>Vaccine Brand</p></td><td><p>Total number of reports</p></td><td><p>Number of serious reports (% of total)</p></td></tr><tr><td><p>Cervarix</p></td><td><p>6,260</p></td><td><p>1,762 (28%)</p></td></tr><tr><td><p>Gardasil</p></td><td><p>1,200</p></td><td><p>459 (38%)</p></td></tr><tr><td><p>HPV Brand unspecified</p></td><td><p>488</p></td><td><p>308 (63%)</p></td></tr><tr><td><p>Total</p></td><td><p>7,948*</p></td><td><p>2529 (32%)</p></td></tr></tbody></table><p> </p><p><em>Note:</em></p><p> </p><p>*The total number of reports received will not equal the total in the table above as some reports may have more than one suspect vaccine.</p><p> </p><p> </p><p> </p><p>The MHRA does not hold data on age-specific usage therefore we are unable to provide the age-specific rate that these figures represent. The MHRA continually reviews safety of the vaccine and, following administration of over 7 million doses in the UK alone, no serious new risks have been identified. The benefits in protecting against HPV-related disease far outweigh any possible side effects of the vaccine.</p><p> </p>
	creator	1861 label Biography information for The Countess of Mar
	publisher	25277
	tabling member	1861 label Biography information for The Countess of Mar

170707

	human indexable
	published
	registered interest
	answer date	05/01/2015
	date	16/12/2014
	date tabled	16/12/2014
	ddp created	16/12/2014 22:11:46
	ddp modified	08/02/2015 17:46:27
	answering body	Department of Health
	question status	Tabled
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus: Vaccination
	house id	1
	identifier	218969
	legislature	25259
	parliament number	55
	question first answered	05/01/2015 17:59:38
	question text	To ask the Secretary of State for Health, when he expects the Joint Committee on Vaccination and Innoculation to make a recommendation on whether all adolescent boys should be included in the national HPV vaccination programme.
	session	2014/15
	session number	4
	tabling member constituency	Basildon and Billericay
	tabling member printed	Mr John Baron
	title	House of Commons Tabled Parliamentary Question 2014/15 218969
	type	WrittenParliamentaryQuestion
	uin	218969
	version	1
	written parliamentary question type	NamedDay
	answer	answer answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI), the body that advises the government on all immunisation matters has set up a human papillomavirus (HPV) sub-committee to consider a number of key issues on HPV vaccination, including the routine vaccination of adolescent boys.</p><p> </p><p> </p><p> </p><p>The HPV sub-committee will report its findings to the JCVI following consideration of work modelling the impact and cost-effectiveness of extending HPV vaccination to adolescent boys. We are advised that it is currently anticipated that a model being developed at Warwick University can be presented to the HPV sub-committee in the second half of 2015. A separate model being developed by Public Health England may not be completed until early 2017.</p><p> </p><p> </p><p> </p><p>We are furthermore advised that the JCVI and sub-committee may need to consider both studies before taking a final view on the impact and cost-effectiveness of extending HPV vaccination to adolescent boys and may therefore not be in a position to do so before early 2017.</p><p> </p><p> </p><p> </p>
	creator	1390 label Biography information for Mr John Baron
	publisher	25259
	tabling member	1390 label Biography information for Mr John Baron

175751

	human indexable
	published
	registered interest
	answer date	28/01/2015
	date	26/01/2015
	date tabled	26/01/2015
	ddp created	27/01/2015 01:01:25
	ddp modified	09/02/2015 00:38:41
	answering body	Department of Health
	question status	Tabled
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus: Vaccination
	house id	1
	identifier	221935
	legislature	25259
	parliament number	55
	question first answered	02/02/2015 17:36:54
	question text	To ask the Secretary of State for Health, what discussions he has had with Public Health England on targeted campaigns in regions where HPV vaccination rates have fallen below the national average; and if he will make a statement.
	session	2014/15
	session number	4
	tabling member constituency	Easington
	tabling member printed	Grahame M. Morris
	title	House of Commons Tabled Parliamentary Question 2014/15 221935
	type	WrittenParliamentaryQuestion
	uin	221935
	version	1
	written parliamentary question type	Ordinary
	answer	answer answer text <p>We have not had any discussion with Public Health England on targeted campaigns in regions where the human papillomavirus vaccination coverage rates have fallen below the national average.</p><p> </p><p> </p><p> </p><p>Under the NHS public health functions agreement between the Secretary of State and NHS England, NHS England is responsible for improving or at least maintaining vaccination coverage in line with relevant performance indicators in the agreement, whilst reducing variations in local levels of performance between geographical areas. NHS England commissioning teams have access to a data repository which provides comparisons of relative performance by local areas and providers and enables improvement plans to be put in place where appropriate.</p><p> </p><p> </p><p> </p>
	creator	3973 label Biography information for Grahame Morris
	publisher	25259
	tabling member	3973 label Biography information for Grahame Morris

223318

	human indexable
	published
	registered interest
	answer date	26/02/2015
	date	24/02/2015
	date tabled	24/02/2015
	ddp created	24/02/2015 23:18:32
	ddp modified	03/03/2015 14:52:05
	answering body	Department of Health
	question status	Tabled
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus: Vaccination
	house id	1
	identifier	225143
	legislature	25259
	parliament number	55
	question first answered	03/03/2015 14:20:02
	question text	To ask the Secretary of State for Health, when vaccinations for human papillomavirus for men who have sex with men will be implemented.
	session	2014/15
	session number	4
	tabling member constituency	Totnes
	tabling member printed	Dr Sarah Wollaston
	title	House of Commons Tabled Parliamentary Question 2014/15 225143
	type	WrittenParliamentaryQuestion
	uin	225143
	version	1
	written parliamentary question type	Ordinary
	answer	answer answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI), the independent expert body that advises the Government on all immunisation matters agreed at its October meeting that further consultation was needed with stakeholders before finalising its advice to ministers on the human papillomavirus (HPV) vaccination of men who have sex with men (MSM). It held a stakeholder consultation between 12 November and 7 January and we understand that the JCVI considered the outcome of the consultation at its meeting on 4 February 2015, as it reviewed its provisional advice on MSM.</p><p> </p><p> </p><p> </p><p>Any implementation of an HPV MSM vaccination programme will be dependent on the JCVI’s final advice. We look forward to receiving the JCVI’s final advice in due course.</p><p> </p>
	creator	4073 label Biography information for Dr Sarah Wollaston
	publisher	25259
	tabling member	4073 label Biography information for Dr Sarah Wollaston

223639

	human indexable
	published
	registered interest
	answer date	27/02/2015
	date	25/02/2015
	date tabled	25/02/2015
	ddp created	25/02/2015 22:58:54
	ddp modified	04/03/2015 14:35:08
	answering body	Department of Health
	question status	Tabled
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus: Vaccination
	house id	1
	identifier	225307
	legislature	25259
	parliament number	55
	question first answered	04/03/2015 14:03:29
	question text	To ask the Secretary of State for Health, when he expects his Department to be in a position to make a decision on HPV vaccination for adolescent boys.
	session	2014/15
	session number	4
	tabling member constituency	Basildon and Billericay
	tabling member printed	Mr John Baron
	title	House of Commons Tabled Parliamentary Question 2014/15 225307
	type	WrittenParliamentaryQuestion
	uin	225307
	version	1
	written parliamentary question type	Ordinary
	answer	answer answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) is the independent expert body that advises the Government on all immunisation matters including human papilloma virus (HPV) vaccination. JCVI has set up a HPV sub-committee which is giving consideration to work modelling the impact and cost-effectiveness of extending HPV vaccination to adolescent boys.</p><p> </p><p> </p><p> </p><p>It is anticipated that a model being developed at Warwick University could be presented to the sub-committee in the second half of this year. A separate model being developed by Public Health England may not now be completed until early 2017. JCVI and its HPV sub-committee may need to consider both studies before taking a final view on the impact and cost-effectiveness of extending HPV vaccination to adolescent boys and may therefore not be in a position to do so before early 2017.</p><p> </p><p> </p><p> </p><p>Any implementation of an HPV boys vaccination programme will be dependent on JCVI’s final advice.</p><p> </p>
	creator	1390 label Biography information for Mr John Baron
	publisher	25259
	tabling member	1390 label Biography information for Mr John Baron

223640

	human indexable
	published
	registered interest
	answer date	27/02/2015
	date	25/02/2015
	date tabled	25/02/2015
	ddp created	25/02/2015 22:58:57
	ddp modified	04/03/2015 18:00:05
	answering body	Department of Health
	question status	Tabled
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus: Vaccination
	house id	1
	identifier	225308
	legislature	25259
	parliament number	55
	question first answered	04/03/2015 17:28:50
	question text	To ask the Secretary of State for Health, if he will bring forward the timeline for the review and recommendation in respect of the introduction of a universal HPV vaccination programme.
	session	2014/15
	session number	4
	tabling member constituency	Basildon and Billericay
	tabling member printed	Mr John Baron
	title	House of Commons Tabled Parliamentary Question 2014/15 225308
	type	WrittenParliamentaryQuestion
	uin	225308
	version	1
	written parliamentary question type	Ordinary
	answer	answer answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) is the independent expert body that advises the Government on all immunisation matters including human papillomavirus (HPV) vaccination.</p><p> </p><p> </p><p> </p><p>HPV is currently recommended for adolescent girls aged 12-13 years.</p><p> </p><p> </p><p> </p><p>The JCVI is currently considering possible extension to the programme, including to men who have sex with men (MSM) and adolescent boys. The JCVI is not considering a universal HPV vaccination programme.</p><p> </p><p> </p><p> </p><p>Detailed cost effectiveness analysis is required to fully understand the potential benefits of any proposals. It is essential that the JCVI does its work thoroughly and comprehensively before finalising its advice to the Government.</p><p> </p><p> </p><p> </p>
	creator	1390 label Biography information for Mr John Baron
	publisher	25259
	tabling member	1390 label Biography information for Mr John Baron

223641

	human indexable
	published
	registered interest
	answer date	27/02/2015
	date	25/02/2015
	date tabled	25/02/2015
	ddp created	25/02/2015 22:58:59
	ddp modified	04/03/2015 15:22:02
	answering body	Department of Health
	question status	Tabled
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus: Vaccination
	house id	1
	identifier	225309
	legislature	25259
	parliament number	55
	question first answered	04/03/2015 14:50:09
	question text	To ask the Secretary of State for Health, when he expects a decision to be made on introducing HPV vaccinations for men who have sex with men.
	session	2014/15
	session number	4
	tabling member constituency	Basildon and Billericay
	tabling member printed	Mr John Baron
	title	House of Commons Tabled Parliamentary Question 2014/15 225309
	type	WrittenParliamentaryQuestion
	uin	225309
	version	1
	written parliamentary question type	Ordinary
	answer	answer answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI), the independent expert body that advises the Government on all immunisation matters agreed at its October meeting that further consultation was needed with stakeholders before finalising its advice to Ministers on the human papilloma virus (HPV) vaccination of men who have sex with men (MSM). It held a stakeholder consultation between 12 November and 7 January and we understand that JCVI considered the outcome of the consultation at its meeting on 4 February 2015, as it reviewed its provisional advice on MSM.</p><p> </p><p> </p><p> </p><p>Any implementation of an HPV MSM vaccination programme will be dependent on JCVI’s final advice. We look forward to receiving JCVI’s final advice in due course.</p><p> </p>
	creator	1390 label Biography information for Mr John Baron
	publisher	25259
	tabling member	1390 label Biography information for Mr John Baron

223642

	human indexable
	published
	registered interest
	answer date	27/02/2015
	date	25/02/2015
	date tabled	25/02/2015
	ddp created	25/02/2015 22:59:01
	ddp modified	04/03/2015 17:37:02
	answering body	Department of Health
	question status	Tabled
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus: Vaccination
	house id	1
	identifier	225305
	legislature	25259
	parliament number	55
	question first answered	04/03/2015 17:05:46
	question text	To ask the Secretary of State for Health, for what reason Public Health England is undertaking additional cost effectiveness modelling for the HPV vaccine and adolescent boys.
	session	2014/15
	session number	4
	tabling member constituency	Basildon and Billericay
	tabling member printed	Mr John Baron
	title	House of Commons Tabled Parliamentary Question 2014/15 225305
	type	WrittenParliamentaryQuestion
	uin	225305
	version	1
	written parliamentary question type	Ordinary
	answer	answer answer text <p>In 2008 when forming its recommendation for vaccination against the human papilloma virus (HPV) in the United Kingdom the Joint Committee on Vaccination and Immunisation (JCVI) did not recommend vaccination of boys because the evidence from modelling undertaken by the Health Protection Agency (now Public Health England (PHE)) indicated vaccinating boys was unlikely to be cost-effective (Jit et al., 2008).</p><p> </p><p> </p><p> </p><p>JCVI keeps the eligibility criteria of all vaccination programmes under review. In October 2013 JCVI recommended a HPV sub-committee be formed to consider a number of issues including the potential extension of the programme to include adolescent boys, because of new and emerging evidence on the association of HPV vaccine types with non-cervical cancers. JCVI requested that modelling be undertaken by PHE to re-examine the impact and cost-effectiveness of extending the HPV vaccination programme to adolescent boys in light of this evidence. The Department has also commissioned the University of Warwick to conduct an independent modelling assessment on vaccinating adolescent boys.</p><p> </p>
	creator	1390 label Biography information for Mr John Baron
	publisher	25259
	tabling member	1390 label Biography information for Mr John Baron

223643

	human indexable
	published
	registered interest
	answer date	27/02/2015
	date	25/02/2015
	date tabled	25/02/2015
	ddp created	25/02/2015 22:59:03
	ddp modified	04/03/2015 16:17:06
	answering body	Department of Health
	question status	Tabled
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus: Vaccination
	house id	1
	identifier	225306
	legislature	25259
	parliament number	55
	question first answered	04/03/2015 15:45:36
	question text	To ask the Secretary of State for Health, for what reasons Public Health England did not commence its cost effectiveness modelling for HPV vaccination for adolescent boys until 2015.
	session	2014/15
	session number	4
	tabling member constituency	Basildon and Billericay
	tabling member printed	Mr John Baron
	title	House of Commons Tabled Parliamentary Question 2014/15 225306
	type	WrittenParliamentaryQuestion
	uin	225306
	version	1
	written parliamentary question type	Ordinary
	answer	answer answer text <p>On the advice of the Joint Committee on Vaccination and Immunisation, Public Health England (PHE) agreed to analyse the impact and cost effectiveness of gender neutral human papilloma virus (HPV) vaccination using an HPV cervical screening model already being developed within PHE. This work was planned to follow the completion of a model to look at the cost-effectiveness of HPV vaccination of men who have sex with men in sexual health clinics. Quality assurance processes have led to a delay in completion of the HPV cervical screening model, which has delayed the commencement of the modelling work on adolescent boys.</p><p> </p>
	creator	1390 label Biography information for Mr John Baron
	publisher	25259
	tabling member	1390 label Biography information for Mr John Baron